Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials.

Fatemeh G, Sajjad M, Niloufar R, et al. (2022) Journal of neurology
Title and abstract of Effect of melatonin supplementation on sleep quality: a systematic review and meta-analysis of randomized controlled trials.

Key Takeaway

Melatonin significantly improves sleep quality (PSQI WMD -1.24), with particularly strong effects in people with respiratory diseases and metabolic disorders.

Summary

This systematic review and meta-analysis examined 23 RCTs (from 2,642 screened papers) evaluating melatonin supplementation's effect on sleep quality using the Pittsburgh Sleep Quality Index (PSQI). The study provides condition-specific evidence for melatonin's efficacy.

Overall, melatonin significantly improved sleep quality (WMD: -1.24, 95% CI: -1.77 to -0.71, p < 0.001), though with substantial heterogeneity (I-squared = 80.7%). Subgroup analysis revealed the strongest effects in patients with respiratory diseases (WMD: -2.20) and metabolic disorders (WMD: -2.74), with more modest effects in primary sleep disorders (WMD: -0.67).

Importantly, melatonin did not significantly improve sleep quality in people with mental disorders, neurodegenerative diseases, or certain other conditions, suggesting its benefits are condition-dependent rather than universal.

Methods

  • Systematic review of 2,642 papers, 23 RCTs met inclusion criteria
  • Pittsburgh Sleep Quality Index (PSQI) as primary outcome measure
  • Random-effects meta-analysis
  • Subgroup analyses by health condition and intervention type
  • Sources of heterogeneity assessed (health status, intervention type)

Key Results

  • Overall sleep quality improved: WMD -1.24 (95% CI: -1.77, -0.71, p < 0.001)
  • Substantial heterogeneity: I-squared = 80.7%
  • Respiratory diseases: WMD -2.20 (95% CI: -2.97, -1.44) - strongest effect
  • Metabolic disorders: WMD -2.74 (95% CI: -3.48, -2.00)
  • Primary sleep disorders: WMD -0.67 (95% CI: -0.98, -0.37)
  • Not significant for mental disorders, neurodegenerative diseases, or other conditions

Limitations

  • High heterogeneity across studies (I-squared = 80.7%)
  • PSQI is a subjective self-report measure
  • Variable melatonin doses and formulations across studies
  • Health status significantly moderated effects, limiting generalizability
  • Limited number of studies in some subgroup analyses
  • Publication bias not fully assessed

Related Interventions

Related Studies

Source

View on PubMed →

DOI: 10.1007/s00415-020-10381-w